TEMHealthcare · Health Information ServicesThe 20 Wall Street analysts covering Tempus AI, Inc. hold a median 12-month price target of $75 — +9.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 12 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Tempus AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (77): Analysts have, on balance, been raising their forecasts.
Volatility (16): The share price moves around a lot.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TEM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.9% from it.
Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | Canaccord Genuity | Maintains | Buy | $80 → $95 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $65 → $92 |
| 21 Sept 2026 | Goldman Sachs | Initiates | Neutral | — |
| 21 Sept 2026 | Goldman Sachs | Initiates | Neutral | $75 |
| 11 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $56 → $66 |
| 9 Sept 2026 | UBS | Initiates | Neutral | $70 |
| 9 Sept 2026 | UBS | Initiates | Neutral | — |
| 8 Sept 2026 | Roth Capital | Initiates | Neutral | — |
| 8 Sept 2026 | Roth Capital | Initiates | Neutral | $67 |
| 8 Sept 2026 | Rothschild & Co | Initiates | Neutral | — |
| 8 Sept 2026 | Rothschild & Co | Initiates | Neutral | $67 |
| 2 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 2 Sept 2026 | Cantor Fitzgerald | Initiates | Overweight | $80 |
| 1 Sept 2026 | Piper Sandler | Upgrade | Overweight | $56 → $76 |
| 1 Sept 2026 | Piper Sandler | Upgrade | Overweight | — |
| 31 Aug 2026 | Freedom Capital Markets | Maintains | Hold | $51 → $73 |
| 31 Aug 2026 | Freedom Capital Markets | Maintains | Hold | — |
| 20 Aug 2026 | BTIG | Maintains | Buy | $70 → $80 |
| 20 Aug 2026 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TEM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Oct 2026, Tempus AI, Inc. returned −27.8% against +18.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 16% of US stocks
Cheaper than 4% of US stocks
Cheaper than 95% of US stocks
Higher than 71% of US stocks
Higher than 60% of US stocks
Higher than 78% of US stocks
Higher than 21% of US stocks
Higher than 16% of US stocks
Higher than 18% of US stocks
Higher than 28% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tempus AI, Inc. has a market value of $12.8B and an enterprise value of $13.1B.
Revenue in the twelve months to 30 June 2026: $1.4B. The latest quarter grew 21.6% year on year.
Net income over the same four quarters: −$254.4M, a −17.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$273.0M, after $9.8M of capital spending.
Trailing P/E: 39.3×; forward P/E: −8304.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Tempus AI, Inc. employs 3,800 people — $377K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Tempus AI, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ambry Genetics, a wholly owned Tempus AI subsidiary, announced GenomeNext and GenomeReveal, a whole genome sequencing solution intended to help improve diagnosis for patients with rare diseases.
Why it matters — The announcement concerns a clinical genomic testing offering from a Tempus AI subsidiary.
Tempus AI is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion. The collaborations are described as paving the way for future revenue growth.
Why it matters — TEM watchers may note the partnerships as part of the company’s efforts to expand its precision medicine footprint and support future revenue growth.
The item says Tempus AI’s data licensing growth, AI-driven innovations and rising shares support holding the stock, while its premium valuation and reimbursement risks warrant caution.
Why it matters — TEM watchers may weigh the company’s growth drivers against valuation and reimbursement concerns.
Tempus expanded its multi-year collaboration involving intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy, in combination with Keytruda for completely resected stage IIB-IV melanoma and other cancer types.
Why it matters — The expanded collaboration is relevant to TEM watchers tracking the company’s work in cancer-treatment partnerships and infrastructure.
Tempus announced an expanded, multi-year collaboration with Moderna and Merck related to the potential commercialization of intismeran autogene, an individualized neoantigen therapy being evaluated with KEYTRUDA in patients with resected stage IIB-IV melanoma and other cancer types.
Why it matters — The collaboration expands Tempus's involvement in work connected to a therapy under evaluation across melanoma and other cancer types.
The 20 Wall Street analysts covering Tempus AI, Inc. have a median 12-month price target of $75, with estimates ranging from $35 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 analysts covering Tempus AI, Inc., 10 rate it a Buy, 9 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Tempus AI, Inc. 24 out of 100 across roughly 4,600 US stocks as at 12 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Oct 2026, Tempus AI, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (77 of 100).
No one can know that. What the data says: the median 12-month target from 20 analysts implies +9.9% from the last close, and Ticker Nerd's factor model ranks Tempus AI, Inc. 24 out of 100 as at 12 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Tempus AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $100 over the next 12 months.
Tempus AI, Inc. returned -27.8% over the 12 months to 13 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development.
The most recent item we track (Business Wire, 13 Oct 2026): "Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases". Ambry Genetics, a wholly owned Tempus AI subsidiary, announced GenomeNext and GenomeReveal, a whole genome sequencing solution intended to help improve diagnosis for patients with rare diseases.
Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development. Its current business is organized around genomics, data, and artificial intelligence applications, with products spanning next-generation sequencing, molecular profiling, clinical decision support, and software-based diagnostic tools. Tempus AI serves healthcare providers, researchers, and pharmaceutical and biotechnology companies across oncology and other clinical areas, including cardiology, neuropsychiatry, infectious disease, and radiology. The stock represents ownership in a company positioned at the intersection of healthcare, data analytics, and diagnostic innovation.
CEO Mr. Eric P. Lefkofsky J.D. · 3,800 employees · United States · https://www.tempus.com
